JP2019526541A - 大麻組成物 - Google Patents

大麻組成物 Download PDF

Info

Publication number
JP2019526541A
JP2019526541A JP2019505187A JP2019505187A JP2019526541A JP 2019526541 A JP2019526541 A JP 2019526541A JP 2019505187 A JP2019505187 A JP 2019505187A JP 2019505187 A JP2019505187 A JP 2019505187A JP 2019526541 A JP2019526541 A JP 2019526541A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
terpene fraction
weight
amount
cannabis extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019505187A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019526541A5 (cg-RX-API-DMAC7.html
Inventor
カレリス、ハリー
ゴードン、マラ
スミス、スチュワート
ウォッシャー、スチュワート
Original Assignee
ゼルダ セラピューティクス オペレーションズ ピーティーワイ リミテッド
ゼルダ セラピューティクス オペレーションズ ピーティーワイ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65524553&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2019526541(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2017901222A external-priority patent/AU2017901222A0/en
Application filed by ゼルダ セラピューティクス オペレーションズ ピーティーワイ リミテッド, ゼルダ セラピューティクス オペレーションズ ピーティーワイ リミテッド filed Critical ゼルダ セラピューティクス オペレーションズ ピーティーワイ リミテッド
Publication of JP2019526541A publication Critical patent/JP2019526541A/ja
Publication of JP2019526541A5 publication Critical patent/JP2019526541A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019505187A 2016-08-03 2017-08-03 大麻組成物 Pending JP2019526541A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662370299P 2016-08-03 2016-08-03
US62/370,299 2016-08-03
AU2017901222A AU2017901222A0 (en) 2017-04-04 Cannabis composition
AU2017901222 2017-04-04
AU2017902065A AU2017902065A0 (en) 2017-05-31 Cannabis composition
AU2017902065 2017-05-31
PCT/AU2017/050817 WO2018023166A1 (en) 2016-08-03 2017-08-03 Cannabis composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020204014A Division JP7139559B2 (ja) 2016-08-03 2020-12-09 大麻組成物

Publications (2)

Publication Number Publication Date
JP2019526541A true JP2019526541A (ja) 2019-09-19
JP2019526541A5 JP2019526541A5 (cg-RX-API-DMAC7.html) 2020-01-23

Family

ID=65524553

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019505187A Pending JP2019526541A (ja) 2016-08-03 2017-08-03 大麻組成物
JP2020204014A Active JP7139559B2 (ja) 2016-08-03 2020-12-09 大麻組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020204014A Active JP7139559B2 (ja) 2016-08-03 2020-12-09 大麻組成物

Country Status (15)

Country Link
US (2) US11304925B1 (cg-RX-API-DMAC7.html)
EP (1) EP3493800A4 (cg-RX-API-DMAC7.html)
JP (2) JP2019526541A (cg-RX-API-DMAC7.html)
KR (3) KR102447510B1 (cg-RX-API-DMAC7.html)
CN (1) CN109789123A (cg-RX-API-DMAC7.html)
AU (4) AU2017305103B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019001794A2 (cg-RX-API-DMAC7.html)
CA (1) CA3031300A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019000266A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019001043A2 (cg-RX-API-DMAC7.html)
IL (1) IL264458B (cg-RX-API-DMAC7.html)
MX (1) MX386086B (cg-RX-API-DMAC7.html)
PE (2) PE20230607A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201900501RA (cg-RX-API-DMAC7.html)
WO (1) WO2018023166A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023529476A (ja) * 2020-06-12 2023-07-10 ゼリラ セラピューティクス オペレーションズ ピーティーワイ リミテッド 慢性疼痛を治療するための組成物及び方法

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210013645A (ko) 2016-08-03 2021-02-04 젤다 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 카나비스 조성물
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
CN110944632A (zh) 2017-06-19 2020-03-31 塞尔达治疗手术有限公司 睡眠障碍组合物及其治疗
CA3103178A1 (en) * 2017-06-27 2019-01-03 Enviro BioMedical Laboratories Inc. Blended cannabis compounds and methods of making the same
US20200276155A1 (en) * 2017-09-15 2020-09-03 Zelda Therapeutics Operations Pty Ltd Composition and method for treating autism
EP3745884A1 (en) 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
WO2019199861A2 (en) * 2018-04-09 2019-10-17 Ellevet Sciences Hemp extract for treatment of pain in animals
WO2019227167A1 (en) * 2018-06-01 2019-12-05 The University Of Sydney Compositions and treatments
EP3807385A1 (en) * 2018-06-14 2021-04-21 Biosoma B.V. Process for the extraction of oil-soluble components from plant material
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol
WO2020084423A1 (en) * 2018-10-24 2020-04-30 Radient Technologies Innovations Inc. Extraction-based contract execution
WO2020121312A1 (en) * 2018-12-12 2020-06-18 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Compositions and methods for the treatment of cutaneous t cell lymphoma (ctcl)
NL2022615B1 (en) * 2019-02-21 2020-08-31 Patrick Alexander Unger Pharmaceutical composition comprising tetrahydrocannabivarin for the prevention and treatment of overweight
CN113784704A (zh) * 2019-04-17 2021-12-10 诺狄更斯公司 快速崩解大麻素片剂
EP4041000A1 (en) * 2019-10-09 2022-08-17 Nicoventures Trading Limited Aerosolisable material
US12011471B2 (en) * 2019-12-19 2024-06-18 Atlas365 Incorporated Extracts enriched with polyphenolic compounds and related methods
CN115605289A (zh) * 2020-04-29 2023-01-13 利加尔有限合伙公司（Nz） 印迹聚合物及其使用方法
KR20220126653A (ko) * 2021-03-08 2022-09-16 주식회사 엘지생활건강 칸나비게롤을 포함하는 조성물
IL307444A (en) * 2021-04-05 2023-12-01 The State Of Israel Ministry Of Agriculture & Rural Development Agricultural Res Organization Aro Vo Preparations and methods for the treatment of cancer
US12440454B2 (en) 2022-02-01 2025-10-14 Portland Technology Holdings Llc Pharmaceutical compositions containing hemp extract for administration to felines and related methods
WO2025231524A1 (en) * 2024-05-08 2025-11-13 Heyday RX Pty Ltd Cannabinoid compositions

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008523078A (ja) * 2004-12-09 2008-07-03 インシス セラピューティクス，インコーポレーテッド 室温で安定なドロナビノール製剤
US20120263785A1 (en) * 2006-11-10 2012-10-18 Johnson Matthey Public Limited Company Stable cannabinoid compositions and methods for making and storing them
JP2013522184A (ja) * 2010-03-12 2013-06-13 ジーダブリュー・ファーマ・リミテッド がんの治療におけるフィトカンナビノイド
JP2014530247A (ja) * 2011-10-18 2014-11-17 ジーダブリュー・ファーマ・リミテッドＧｗ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ 乳がんの治療に使用されるフィトカンナビノイド
WO2016030369A1 (en) * 2014-08-25 2016-03-03 Janing Holding Aps Device with compositions for delivery to the lungs, the oral mucosa and the brain

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10051427C1 (de) * 2000-10-17 2002-06-13 Adam Mueller Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte
GB2418612A (en) 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
WO2007032962A2 (en) 2005-09-09 2007-03-22 University Of Kentucky Compositions and methods for intranasal delivery of tricyclic cannabinoids
CN104619318A (zh) * 2012-05-03 2015-05-13 回音制药公司 含有δ9-四氢大麻酚的大麻植物分离物及其制备方法
US10792318B2 (en) 2013-03-14 2020-10-06 Sc Laboratories, Inc. Bioactive concentrates and uses thereof
WO2014145490A2 (en) 2013-03-15 2014-09-18 Biotech Institute, Llc Breeding, production, processing and use of specialty cannabis
HRP20191097T1 (hr) 2013-10-29 2019-09-20 Biotech Institute, Llc Uzgoj, proizvodnja, obrada i upotreba specijalnog kanabisa
US9044390B1 (en) 2014-04-17 2015-06-02 Gary J. Speier Pharmaceutical composition and method of manufacturing
WO2015200049A1 (en) 2014-06-26 2015-12-30 Island Breeze Systems Ca, Llc Mdi related products and methods of use
BR112017008301B1 (pt) * 2014-10-21 2021-12-07 United Cannabis Corp Extratos de cannabis e métodos de sua preparação e uso
AU2015360349B2 (en) * 2014-12-12 2020-10-08 Ojai Energetics Pbc Microencapsulated cannabinoid compositions
WO2016105514A1 (en) * 2014-12-23 2016-06-30 Biotech Institute, Llc A reliable and robust method for the analysis of cannabinoids and terpenes in cannabis
EP3250200A4 (en) 2015-01-31 2018-09-19 Constance Therapeutics, Inc. Methods for preparation of cannabis oil extracts and compositions
KR20210013645A (ko) 2016-08-03 2021-02-04 젤다 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 카나비스 조성물
EP3493799A4 (en) 2016-08-03 2020-04-01 Zelda Therapeutics Operations Pty Ltd CANNABIS

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008523078A (ja) * 2004-12-09 2008-07-03 インシス セラピューティクス，インコーポレーテッド 室温で安定なドロナビノール製剤
US20120263785A1 (en) * 2006-11-10 2012-10-18 Johnson Matthey Public Limited Company Stable cannabinoid compositions and methods for making and storing them
JP2013522184A (ja) * 2010-03-12 2013-06-13 ジーダブリュー・ファーマ・リミテッド がんの治療におけるフィトカンナビノイド
JP2014530247A (ja) * 2011-10-18 2014-11-17 ジーダブリュー・ファーマ・リミテッドＧｗ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ 乳がんの治療に使用されるフィトカンナビノイド
WO2016030369A1 (en) * 2014-08-25 2016-03-03 Janing Holding Aps Device with compositions for delivery to the lungs, the oral mucosa and the brain

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DRUG TEST.ANALYSIS., vol. Vol.4,No.7-8, JPN6020000863, 2012, pages 660 - 667, ISSN: 0004320139 *
MOLECULES, vol. 19, JPN6020028775, 2014, pages 6694 - 6706, ISSN: 0004320140 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023529476A (ja) * 2020-06-12 2023-07-10 ゼリラ セラピューティクス オペレーションズ ピーティーワイ リミテッド 慢性疼痛を治療するための組成物及び方法

Also Published As

Publication number Publication date
KR20220132674A (ko) 2022-09-30
AU2021205115B2 (en) 2023-06-15
KR20190034576A (ko) 2019-04-02
JP2021054836A (ja) 2021-04-08
AU2018100920B4 (en) 2019-02-07
KR20210129747A (ko) 2021-10-28
AU2019203529A1 (en) 2019-06-06
EP3493800A4 (en) 2020-04-08
US11304925B1 (en) 2022-04-19
PE20230607A1 (es) 2023-04-13
AU2017305103B2 (en) 2019-02-21
IL264458B (en) 2021-06-30
NZ750272A (en) 2021-09-24
AU2017305103A1 (en) 2018-07-05
EP3493800A1 (en) 2019-06-12
US20220202767A1 (en) 2022-06-30
BR112019001794A2 (pt) 2019-05-07
CL2019000266A1 (es) 2019-10-04
AU2019203529B2 (en) 2021-04-29
CA3031300A1 (en) 2018-02-08
AU2018100920A4 (en) 2018-08-02
IL264458A (en) 2019-02-28
MX2019001286A (es) 2019-06-13
WO2018023166A1 (en) 2018-02-08
KR102447510B1 (ko) 2022-09-27
SG11201900501RA (en) 2019-02-27
MX386086B (es) 2025-03-18
JP7139559B2 (ja) 2022-09-21
CO2019001043A2 (es) 2020-06-19
CN109789123A (zh) 2019-05-21
PE20200677A1 (es) 2020-06-11
AU2021205115A1 (en) 2021-08-12

Similar Documents

Publication Publication Date Title
JP7139559B2 (ja) 大麻組成物
AU2021240297B2 (en) Cannabis Composition
AU2018101357A4 (en) Composition and method for treating autism
AU2018100925A4 (en) Cannabinoid composition and method for treating PTSD and/or anxiety
NZ750272B2 (en) Cannabis composition

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A525

Effective date: 20190305

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20190522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191205

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20191205

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20191218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200420

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200619

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200811